PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
Albert Gris‐Oliver, Yasir H. Ibrahim, Martín A. Rivas, Celina García-García, Mònica Sánchez-Guixé, Fiorella Ruíz‐Pace, Cristina Viaplana, José Manuel Pérez-García, Antonio Llombart‐Cussac, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Pilar Antón, Patricia Cozar, María Teresa Calvo, Alejandra Bruna, Joaquı́n Arribas, Carlos Caldas, Rodrigo Dienstmann, Paolo Nucíforo, Mafalda Oliveira, Javier Cortés, Violeta Serra
Topics & Concepts
EribulinPI3K/AKT/mTOR pathwayCancer researchMetastatic breast cancerMedicineBreast cancerProtein kinase BSKBR3Internal medicineOncologyCancerBiologyApoptosisGeneticsHuman breastCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer